AR049177A1 - Polipeptidos y conjugados de interferon-alfa - Google Patents
Polipeptidos y conjugados de interferon-alfaInfo
- Publication number
- AR049177A1 AR049177A1 ARP050102059A ARP050102059A AR049177A1 AR 049177 A1 AR049177 A1 AR 049177A1 AR P050102059 A ARP050102059 A AR P050102059A AR P050102059 A ARP050102059 A AR P050102059A AR 049177 A1 AR049177 A1 AR 049177A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptides
- conjugates
- nucleic acids
- interferon
- alfa
- Prior art date
Links
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 102220598625 5-hydroxytryptamine receptor 1E_F48A_mutation Human genes 0.000 abstract 1
- 102220598658 5-hydroxytryptamine receptor 1E_F65A_mutation Human genes 0.000 abstract 1
- 102220602180 Synaptotagmin-3_F55A_mutation Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57250404P | 2004-05-19 | 2004-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049177A1 true AR049177A1 (es) | 2006-07-05 |
Family
ID=35428915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102059A AR049177A1 (es) | 2004-05-19 | 2005-05-19 | Polipeptidos y conjugados de interferon-alfa |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US7318918B2 (enExample) |
| EP (1) | EP1753779A2 (enExample) |
| JP (1) | JP2008507298A (enExample) |
| CN (1) | CN101115769A (enExample) |
| AR (1) | AR049177A1 (enExample) |
| AU (1) | AU2005245918A1 (enExample) |
| BR (1) | BRPI0511196A (enExample) |
| CA (1) | CA2566247A1 (enExample) |
| IL (1) | IL178470A0 (enExample) |
| MX (1) | MXPA06013412A (enExample) |
| NO (1) | NO20065084L (enExample) |
| RU (1) | RU2006145020A (enExample) |
| TW (1) | TW200611910A (enExample) |
| WO (1) | WO2005113592A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
| ATE439437T1 (de) * | 1999-01-05 | 2009-08-15 | Univ Boston | Verbessertes klonierungsverfahren |
| US7435562B2 (en) * | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
| WO2002008408A2 (en) * | 2000-07-21 | 2002-01-31 | Trustees Of Boston University | Modular vector systems |
| ES2585353T3 (es) * | 2004-05-12 | 2016-10-05 | Synchronoss Technologies, Inc. | Sistema de identificación de contactos avanzado |
| ATE540110T1 (de) * | 2004-11-11 | 2012-01-15 | Modular Genetics Inc | Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt |
| MY167668A (en) * | 2005-03-09 | 2018-09-21 | Superlab Far East Ltd | Uses of recombinant super-compound interferons |
| KR20080019619A (ko) * | 2005-05-18 | 2008-03-04 | 맥시겐, 인크. | 개량된 인터페론-알파 폴리펩티드 |
| AR078117A1 (es) * | 2006-06-20 | 2011-10-19 | Protech Pharma S A | Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina |
| US20080014616A1 (en) * | 2006-07-11 | 2008-01-17 | Kevin Jarrell | Methods of introducing targeted diversity into nucleic acid molecules |
| US20100009908A1 (en) * | 2006-07-25 | 2010-01-14 | Nozomu Nishi | Galectin 9-Polymer Conjugates |
| US7808342B2 (en) * | 2006-10-02 | 2010-10-05 | Skyworks Solutions, Inc. | Harmonic phase tuning filter for RF switches |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| WO2009006579A1 (en) * | 2007-07-05 | 2009-01-08 | Pharmaessentia Corp. | Peptide-polymer conjugates |
| CN101883784B (zh) * | 2007-10-01 | 2014-10-15 | 药华医药股份有限公司 | N-端修饰的干扰素-α |
| WO2009090056A2 (en) * | 2008-01-18 | 2009-07-23 | F. Hoffmann-La Roche Ag | Purification of not-glycosylated polypeptides |
| US7954022B2 (en) * | 2008-01-30 | 2011-05-31 | Alcatel-Lucent Usa Inc. | Apparatus and method for controlling dynamic modification of a scan path |
| MX2011005051A (es) * | 2008-11-17 | 2011-06-01 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. |
| EP2391714B2 (en) | 2009-01-30 | 2019-07-24 | Whitehead Institute for Biomedical Research | Methods for ligation and uses thereof |
| TWI565714B (zh) * | 2011-06-02 | 2017-01-11 | 韓美科學股份有限公司 | 非肽基聚合物－胰島素集合體及其製造方法 |
| JP2014525904A (ja) | 2011-06-28 | 2014-10-02 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | タンパク質連結用クリックケミストリーハンドルを設置するためのソルターゼの使用 |
| CN102358897B (zh) * | 2011-10-31 | 2013-02-13 | 北京三元基因工程有限公司 | 重组人寡腺苷酸合成酶-1的制备方法 |
| WO2015168474A1 (en) * | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
| ES2630106T3 (es) * | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
| JP7008023B2 (ja) | 2015-12-30 | 2022-01-25 | ジェネンテック， インコーポレイテッド | 低減されたポリソルベート分解を有する製剤 |
| ES2877568T3 (es) * | 2016-02-05 | 2021-11-17 | Orionis Biosciences Nv | Agentes de unión de Clec9A |
| RU2650755C1 (ru) * | 2017-05-24 | 2018-04-17 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С |
| KR20220143676A (ko) * | 2020-01-24 | 2022-10-25 | 엘커메스 파마 아일랜드 리미티드 | 정제 방법 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
| US4414150A (en) | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
| ES506955A0 (es) | 1980-11-10 | 1983-02-01 | Genentech Inc | Un procedimiento para producir un polipeptido antiviral. |
| IT1167610B (it) | 1982-01-19 | 1987-05-13 | Cetus Corp | Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| JPS60152058A (ja) * | 1984-01-20 | 1985-08-10 | Toshiba Corp | 半導体記憶装置 |
| EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
| US4695626A (en) * | 1986-07-29 | 1987-09-22 | Pfizer Inc. | 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters |
| SG52537A1 (en) | 1990-10-17 | 1998-09-28 | Amgen Inc | Methods and compositions for the treatment of cell proliferation disorders |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5574138A (en) | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6007805A (en) | 1994-03-07 | 1999-12-28 | Imperial College Of Science And Technology | Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| DE69838552T2 (de) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
| AU775937B2 (en) | 1999-01-14 | 2004-08-19 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| WO2000052153A2 (en) | 1999-03-02 | 2000-09-08 | Maxygen, Inc. | Method to identify ligands for orphan receptors |
| PL352332A1 (en) | 1999-05-19 | 2003-08-11 | Lexigen Pharm Corp | Expression and export of interferon-alpha proteins as fc fusion proteins |
| US20040002474A1 (en) | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
| AU8001300A (en) | 1999-10-07 | 2001-05-10 | Maxygen, Inc. | Ifn-alpha homologues |
| IL149267A0 (en) * | 1999-11-12 | 2002-11-10 | Maxygen Holdings Ltd | Interferon gamma conjugates |
| IL152804A0 (en) | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| AU2002223350A1 (en) | 2000-12-01 | 2002-06-11 | Eleanor N. Fish | Cytokine receptor binding peptides |
| KR100459105B1 (ko) | 2001-02-15 | 2004-12-03 | 선바이오(주) | 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체 |
| AU2003293668A1 (en) | 2002-11-15 | 2004-06-15 | F. Hoffmann-La Roche Ag | Positional isomers of peg ifn alpha 2a |
| NZ540043A (en) | 2002-11-18 | 2007-11-30 | Maxygen Inc | Isolated or recombinant Interferon-alpha polypeptides and conjugates |
-
2005
- 2005-05-18 US US11/132,722 patent/US7318918B2/en not_active Expired - Fee Related
- 2005-05-18 MX MXPA06013412A patent/MXPA06013412A/es unknown
- 2005-05-18 WO PCT/US2005/017471 patent/WO2005113592A2/en not_active Ceased
- 2005-05-18 CA CA002566247A patent/CA2566247A1/en not_active Abandoned
- 2005-05-18 EP EP05751765A patent/EP1753779A2/en not_active Withdrawn
- 2005-05-18 AU AU2005245918A patent/AU2005245918A1/en not_active Abandoned
- 2005-05-18 TW TW094116107A patent/TW200611910A/zh unknown
- 2005-05-18 BR BRPI0511196-0A patent/BRPI0511196A/pt not_active Application Discontinuation
- 2005-05-18 RU RU2006145020/04A patent/RU2006145020A/ru unknown
- 2005-05-18 JP JP2007527427A patent/JP2008507298A/ja active Pending
- 2005-05-18 CN CNA2005800241473A patent/CN101115769A/zh active Pending
- 2005-05-19 AR ARP050102059A patent/AR049177A1/es unknown
-
2006
- 2006-09-13 US US11/531,570 patent/US20070020734A1/en not_active Abandoned
- 2006-09-13 US US11/531,531 patent/US7531630B2/en not_active Expired - Fee Related
- 2006-09-13 US US11/531,557 patent/US7531324B2/en not_active Expired - Fee Related
- 2006-09-14 US US11/532,045 patent/US20070225205A1/en not_active Abandoned
- 2006-09-14 US US11/532,024 patent/US20070225204A1/en not_active Abandoned
- 2006-10-05 IL IL178470A patent/IL178470A0/en unknown
- 2006-11-03 NO NO20065084A patent/NO20065084L/no unknown
-
2007
- 2007-05-04 US US11/744,424 patent/US7541436B2/en not_active Expired - Fee Related
- 2007-08-14 US US11/838,730 patent/US7541163B2/en not_active Expired - Fee Related
- 2007-08-15 US US11/839,493 patent/US7537755B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7531630B2 (en) | 2009-05-12 |
| AU2005245918A1 (en) | 2005-12-01 |
| US20070020235A1 (en) | 2007-01-25 |
| IL178470A0 (en) | 2007-02-11 |
| MXPA06013412A (es) | 2007-01-23 |
| NO20065084L (no) | 2006-12-01 |
| CA2566247A1 (en) | 2005-12-01 |
| US7541163B2 (en) | 2009-06-02 |
| US20080171363A1 (en) | 2008-07-17 |
| JP2008507298A (ja) | 2008-03-13 |
| US7531324B2 (en) | 2009-05-12 |
| TW200611910A (en) | 2006-04-16 |
| CN101115769A (zh) | 2008-01-30 |
| WO2005113592A3 (en) | 2006-04-06 |
| BRPI0511196A (pt) | 2007-12-04 |
| US7318918B2 (en) | 2008-01-15 |
| US20080076710A1 (en) | 2008-03-27 |
| US20070225204A1 (en) | 2007-09-27 |
| EP1753779A2 (en) | 2007-02-21 |
| US20050266465A1 (en) | 2005-12-01 |
| RU2006145020A (ru) | 2008-06-27 |
| US7541436B2 (en) | 2009-06-02 |
| WO2005113592A2 (en) | 2005-12-01 |
| US7537755B2 (en) | 2009-05-26 |
| US20070225205A1 (en) | 2007-09-27 |
| US20070025966A1 (en) | 2007-02-01 |
| US20070020734A1 (en) | 2007-01-25 |
| US20080031853A1 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
| ES2545457T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
| ATE400656T1 (de) | Mini-dystrophin nukleinsäure- und peptidsequenzen | |
| ES2513716T3 (es) | Enzimas lecitina-colesteros acitransferasa modificadas | |
| PT1548032E (pt) | Péptidos kdr e vacinas que os contêm | |
| MX2024015050A (es) | L-asparaginasa modificada | |
| CY1116285T1 (el) | Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα | |
| ES2536974T3 (es) | Péptidos de epítopos del receptor de EGF y usos de los mismos | |
| ES2721172T3 (es) | Una nueva clase de moléculas terapéuticas a base de proteínas | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| EP2573109A3 (en) | Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens | |
| MX2010004371A (es) | Proteasa de streptomyces. | |
| ES2531142T3 (es) | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden | |
| ES2531290T3 (es) | Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas | |
| CO5700788A2 (es) | Composiciones y metodos para inmunoterapia especifica de wt1 | |
| ES2691539T3 (es) | Luciferasas de Oplophorus sintéticas con mayor emisión de luz | |
| CO6251278A2 (es) | Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol | |
| NZ580378A (en) | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells | |
| AR040446A1 (es) | Defensinas de plantas | |
| DK1265914T3 (da) | WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme | |
| AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| CY1114526T1 (el) | Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων | |
| AR087719A2 (es) | Celula de planta transformada, cultivo de tejidos y planta transgenica | |
| ES2507094T3 (es) | Proteína específica del timo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |